Development of implant-type tissue-engineered cartilage for patients with nasal deformity in cleft lip and palate - implant-type tissue-engineered cartilage, which is made by applying autologous auricular chondrocytes to scaffolds consisting of atelocollagen hydrogel and poly-L-lactic acid (PLLA) porous body - Development of implant-type tissue-engineered cartilage for patients with nasal deformity in cleft lip and palate

The University of Tokyo Hospital0 sites3 target enrollmentApril 22, 2011

ConditionsPatients of cleft lip and palate, suffering from severe nasal deformity that needs nasal augmentation and nasal tip correction

Overview

Phase: 未知
Intervention: Not specified
Conditions: Patients of cleft lip and palate, suffering from severe nasal deformity that needs nasal augmentation and nasal tip correction
Sponsor: The University of Tokyo Hospital
Enrollment: 3
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 22, 2011

End Date

March 1, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

The University of Tokyo Hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Patients who conflict with the conditions listed below will be excluded from this research: 1\) Patients who are classified as Class 3 or higher in the ASA physical status by the American Society of Anesthesiologists 2\) Patients who possess or are possible to possess malignant neoplasm 3\) Patients with diabetes melitus 4\) Patients who are possible to possess sepsis or bacteremia 5\) Patients who possess infections that are possible to recur around the surgical sites (ear or nose) 6\) Patients who have received surgical treatments on the surgical sites (nose or cartilage) within one year before the operation 7\) Female patients who are pregnant or are possible to be pregnant, and who are lactating 8\) Patients who are possible to suffer from syphilis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or adult T cell leukemia 9\) Patients who suffer or suffered from autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, Hashimoto's thyroiditis, Graves' disease, polyarteritis, scleroderma, ulcerative colitis, Crohn's disease, Sjogren's syndrome, Reiter's syndrome, or mixed connective tissue disease, and patients whose family suffer or suffered from those diseases 10\) Patients who have past history of anaphylactic reaction 11\) Patients who possess or are possible to possess past history of hypersensitivity or an allergy to collagen preparations, lactic acid polymer preparations, fibroblast growth factor (FGF) preparations, insulin preparations, penicillin, or streptomycin The list of 12\) to 14\) have been omitted here because of space limitation.